Employers Holdings director James Kroner sells $52,000 in stock

[
Employers Holdings director James Kroner sells $52,000 in stock
[og_img]
https://www.investing.com/news/insider-trading-news/employers-holdings-director-james-kroner-sells-52000-in-stock-93CH-3904403

Investing.com

Click Frenzy 2025 is the first major sale of the year – these are the 30+ best expert-picked deals so far

Opera’s new AI agent web browser just reinvented web browsing – here’s 5 ways it could completely change the internet

How to watch India vs Australia live stream online (it’s free)

Click Frenzy 2025 is the first major sale of the year – these are the 30+ best expert-picked deals so far

Ex-Israeli Intelligence Official: Shockwaves of Trump’s “Take Over Gaza” Heard, Felt Across Region

What UK political parties are promising in the 2019 general election

Otto Warmbier’s parents want North Korea to suffer for their son’s death

Could a ‘youthquake’ cause Boris Johnson to lose the general election?

Which Celebrity Styles Americans Copy Most in 2025: New Study

New ‘Westworld’ trailer introduces us to another dystopian tech company

What’s the point of ‘Charlie’s Angels’ without Sam Rockwell dancing?

These striking photos capture the future of human flight

IT stocks slide up to 3% as market rout deepens on trade war jitters

Celltrion receives U.S. FDA approval for STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) biosimilars referencing PROLIA ® and XGEVA ®

China's yuan inches higher on PBOC support as US tariffs loom

Seven & i to reject Couche-Tard takeover bid, Yomiuri says

The YouTuber who has become one of Gen Z’s most beloved celebrities

26 last-minute holiday gifts that are still thoughtful and unique

Practicing gratitude regularly can make you less stressed and sleep better

8 things millennials wish you would just stop getting them for the holidays

Employers Holdings director James Kroner sells $52,000 in stock

IT stocks slide up to 3% as market rout deepens on trade war jitters

Celltrion receives U.S. FDA approval for STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) biosimilars referencing PROLIA ® and XGEVA ®

China's yuan inches higher on PBOC support as US tariffs loom

Seven & i to reject Couche-Tard takeover bid, Yomiuri says

Leave a reply Cancel reply